ANAPTYSBIO, INC 8-K/A

What Happened AnaptysBio, Inc. (ANAB) filed Amendment No. 1 to its Form 8-K on April 24, 2026 (Accession No. 0001193125-26-177317) under Item 9.01 to provide unaudited pro forma financial information related to a planned Spin-Off. The company states the pro forma figures are presented to illustrate estimated effects of the Spin-Off and cautions they are not necessarily indicative of results had the Spin-Off been completed on the dates shown or of future results.

Key Details

• Filing: Amendment No. 1 to Form 8-K filed April 24, 2026 (Item 9.01 - Financial Statements and Exhibits).
• Content: Unaudited pro forma financial information intended to illustrate estimated financial effects of the Spin-Off.
• Disclaimer: The company expressly warns the pro forma data are illustrative and not necessarily representative of actual historical or future performance.

Why It Matters The pro forma financial information gives investors a view of how AnaptysBio's reported financial position and results might look after the Spin-Off, which can aid analysis of post-transaction size, capital structure, and comparative metrics. However, because the data are unaudited and explicitly described as illustrative, investors should treat them as preliminary and rely on audited financials and formal disclosures for definitive valuation or investment decisions.